Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Johnson & Johnson One-Shot Covid Vaccine Recommended for Emergency Use

Published 26/02/2021, 22:30
Updated 26/02/2021, 22:51
© Reuters

© Reuters

By Yasin Ebrahim

Investing.com – An advisory panel to the Food and Drug Administration on Friday recommended approval of emergency authorization for Johnson & Johnson's single-dose Covid-19 vaccine, paving the way for a third vaccine to enter the fray and help lead the fight against the pandemic.  

Johnson & Johnson (NYSE:JNJ) rose 1.6% in aftermarket hours

The FDA could grant that emergency use authorization over the weekend. It comes just days after the agency said the vaccine was 66.1% effective in preventing moderate-to-severe Covid-19 cases after 28 days. 

The efficacy of the drug differed across geographies amid new variants. It was 72% effective in the U.S., 66% in Latin America and 57% in South Africa. While the vaccine was less effective at preventing illness in South Africa, it was still highly effective at preventing severe disease. The pharmaceutical giant's vaccine results, released on late-January Jan. 29, initially drew a lukewarm reaction from market participants following the 90%+ efficacy levels of other vaccines including Moderna (NASDAQ:MRNA)'s and Pfizer (NYSE:PFE)'s mRNA vaccines. 

Analysts, however, welcomed the late-stage initial clinical results and highlighted that JNJ's vaccine, with an 85% effective in preventing severe disease and hospitalizations/death, two primary drivers of the lockdowns and restrictions, would play a key role in reopening of economies. 

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.